CHF6297: a novel potent and selective p38 MAPK inhibitor with robust anti-inflammatory activity and suitable for inhaled pulmonary administration as dry powder
Inhibition of p38 mitogen-activated protein kinase (MAPKs) is a potential therapeutic approach for the treatment of acute and chronic pulmonary inflammatory conditions. Here, we report the in vitro and in vivo characterization of the anti-inflammatory effects of CHF6297, a novel potent and selective...
Saved in:
Main Authors: | Cataldo Martucci (Author), Andrew Dennis Allen (Author), Nadia Moretto (Author), Valentina Bagnacani (Author), Alessandro Fioni (Author), Riccardo Patacchini (Author), Maurizio Civelli (Author), Gino Villetti (Author), Fabrizio Facchinetti (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2024-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Corrigendum: CHF6297: a novel potent and selective p38 MAPK inhibitor with robust anti-inflammatory activity and suitable for inhaled pulmonary administration as dry powder
by: Cataldo Martucci, et al.
Published: (2024) -
CHF6001 Inhibits NF-κB Activation and Neutrophilic Recruitment in LPS-Induced Lung Inflammation in Mice
by: Fabio F. Stellari, et al.
Published: (2019) -
p38 MAPK, microglial signaling, and neuropathic pain
by: Suter Marc R, et al.
Published: (2007) -
Injection of YiQiFuMai powder protects against heart failure via inhibiting p38 and ERK1/2 MAPKs activation
by: Yongwei Nie, et al.
Published: (2022) -
Use of p38 MAPK Inhibitors for the Treatment of Werner Syndrome
by: Mark C. Bagley, et al.
Published: (2010)